Detecting Circulating Endothelial Cells In The Peripheral Blood Of Nsclc Patients And Its Application In The Treatment Of Nsclc Patients

Background Angiogenesis plays a critical role in the growth and metastasis of NSCLC. In recent years, antiangiogenic agents have also been demonstrated to be active against a variety of malignancies, including lung cancer. Recently, anti-angiogenic drugs, alone or in combination with chemotherapeutics, are increasingly used by medical oncologists and angiogenesis. In many cases, however, how to evaluate the effectiveness of anti-angiogenic drugs are still no uniform standard up to now. Circulating endothelial cells have been recognized as a useful biomarker for vascular damage. Recently, CECs were found to be more numerous and viable in cancer patients. Thus, we thought that CEC is likely to be an angiogenesis marker to evaluate the effectiveness of treatment in NSCLC patients.Objective To explore the detecting influence of circulating endothelial cells in NSCLC patients with single fluoresce-labeled monoclonal antibody(CD146) and three fluoresce-labeled monoclonal antibody(sCD45 CD31 CD146) by flow cytometry. And to investigate the anterior-posterior treatment changes of mature circulating endothelial cells and its clinical significance in NSCLC patients.Methods The CECs was detected by flow cytometry with single and three fluoresce–labeled monoclonal antibody in peripheral blood of 60 NSCLC patients and 20 healthy volunteers. Fifty-seven NSCLC patients were divided into the treatment group with operation group and chemotherapy alone or with Endostar groups, mature CECs were measured by flow cytometry in peripheral blood of all NSCLC patients and eighteen healthy subjects.Results①CECs were detected successfully by flow cytometry with single fluoresce-labeled monoclonal antibody and three fluoresce-labeled monoclonal antibodys, there was statistical significance in two methods (p<0.05,respectively).②There was significant positive correlation ( r = 0.834, P<0.0001) between the result s of two methods.③The single fluoresce-labeled monoclonal antibody(CD146) of flow cytometry was better than three fluoresce-labeled monoclonal antibodys(CD45 CD31 CD146).④The mature CECs counts elevated in patients with NSCLC(n=57, mean±SD =(0.33357±0.20060)%) comparing with healthy volunteers(n =20, mean±SD =(0.16923±0.13488)%).⑤After treatment, the amount of mature CECs decreased significantly in the operation group (P =0.003) and chemotherapy with Endostar group (P =0.004), the amount of mature CECs decreased no any significant in the chemotherapy alone group (P =0.148).⑥Furthermore, a statistically significant decrease was observed in patients before and after therapy with early NSCLC(P=0.04),but there was not a statistically significant decrease in patients with advanced NSCLC(P=0.96).Conclusion①Two methods may use in detecting CECs by flow cytometry.②The efficiency of three fluoresce-labeled monoclonal antibody by flow cytometry was superior to single fluoresce-labeled monoclonal antibodys in detecting circulating endothelial cells.③The groups of operation and chemotherapy with Endostar could lead to significantly decrease the numbers of mature circulating endothelial cells in the patients of NSCLC.④The detecting of mature CECs may be a promising predictive marker of the clinical efficacy of the antiangiogenic therapy with NSCLC.